R & D
At Ferrer, science, empathy and innovation come together to transform lives
At Ferrer we promote rigorous clinical trials with the aim of transforming scientific knowledge into solutions that improve the lives of people with unmet medical needs. These studies are essential to advance new therapeutic options and improve the approach to diseases.
Through our clinical trials, we generate solid evidence on the safety, efficacy and value of our investigational treatments, contributing to informed decision-making by health authorities, health professionals and health systems.
During the design and execution of studies, we maintain a firm commitment to the ethical principles of clinical research, ensuring the protection of the rights, safety and well-being of participants, as well as the quality and integrity of the data generated. All trials are carried out in accordance with international ethical standards and the applicable regulations in each country.
In addition, we promote a collaborative approach in all phases of clinical research, working together with the scientific community, researchers, organizations and patient representatives to strengthen the design, quality and scope of our studies, always keeping the focus on the people who participate in them.
Real-life comparative effectiveness study of Tyvaso® (inhaled treprostinil ) in the treatment of pulmonary hypertension associated with interstitial lung disease: an external comparative study of inhaled treprostinil versus standard treatment in Europe.
Efficacy of inhaled treprostinil versus standard of care for the treatment of pulmonary hypertension associated with interstitial lung disease: a propensity score-weighted study from the INCREASE trial and registry data from Europe.
Expanded access program and real-life data collection using inhaled treprostinil for the treatment of adults with pulmonary hypertension associated with interstitial lung disease.
A non-interventional, retrospective, prospective study to collect data on the use, safety, and efficacy of parenteral treprostinil in neonates with pulmonary hypertension.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants with Huntington's Disease.
Phase 2/3, open-label study to evaluate the safety of pridopidine in participants with Huntington's disease.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Patients With Amyotrophic Lateral Sclerosis .
A randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, and pharmacokinetics of FNP-223 (oral formulation) for the treatment of progressive supranuclear palsy (PSP).
Multinational registry of patients in secondary cardiovascular prevention.
Ferrer and Prilenia Announce Start of PRECISE-HD Confirmatory Clinical Trial of Pridopidine in Huntington's Disease
First participant in Europe in the Phase 3 clinical trial "PREVAiLS" with pridopidine, in ALS
IMPAHCT celebrates its eighth edition by reinforcing the comprehensive approach to rare lung diseases
Ferrer Spain promotes the foundations of a new value-based public procurement model
We completed the recruitment of 220 patients for PROSPER, the Phase II clinical trial in progressive supranuclear palsy
Update date: July 2026
